San Diego– TriLink BioTechnologies has entered into a non-exclusive license and supply agreement with Quantoom Biosciences, granting the RNA platform company access to TriLink’s industry-leading CleanCap® mRNA capping technology. The collaboration aims to accelerate the production of mRNA and self-amplifying RNA (saRNA)-based vaccines and therapeutics, with a focus on increasing access in developing countries and underserved regions.
Under the agreement, Quantoom will integrate CleanCap into its Ntensify® (sa)mRNA manufacturing platform. The partnership allows Quantoom’s customers to leverage CleanCap’s co-transcriptional capping method, which provides over 95% capping efficiency and significantly improves yield and processing time compared to traditional methods. This could streamline the development of RNA-based products from early research through clinical development.
“Strengthening global health against infectious diseases requires strong industry partnerships,” said Becky Buzzeo, Chief Commercial Officer at Maravai LifeSciences, TriLink’s parent company. “We’re pleased to support Quantoom’s efforts to make RNA-based medicines more accessible, particularly in regions that lack adequate infrastructure.”
TriLink’s CleanCap technology, launched in 2017, has become a cornerstone of the mRNA vaccine landscape and is used in most currently approved mRNA and saRNA COVID-19 vaccines. Its role in speeding up and improving RNA production has made it a go-to solution for companies developing advanced biologics.
Quantoom, a Belgium-based company focused on scalable RNA manufacturing, sees the agreement as a crucial step in its mission to democratize RNA technology. “By incorporating CleanCap into our Ntensify platform, we’re providing researchers and manufacturers with the tools they need to deliver life-saving therapies to communities that need them most,” said José Castillo, CEO of Quantoom Biosciences.
The partnership is expected to support the continued development of RNA medicines targeting infectious diseases and other critical health challenges worldwide, reinforcing both companies’ commitment to global health equity through cutting-edge biotechnology.
